Pictet-Biotech HP CHFRegister to Unlock Ratings |
Performance History | 30/04/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 33.2 | -11.7 | -9.3 | 12.7 | -12.0 | |
+/-Cat | - | - | - | - | - | |
+/-B’mrk | - | - | - | - | - | |
Category: Other Equity | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 06/05/2024 | CHF 644.91 | |
Day Change | -1.56% | |
Morningstar Category™ | Other Equity | |
ISIN | LU0843168732 | |
Fund Size (Mil) 06/05/2024 | USD 1555.81 | |
Share Class Size (Mil) 06/05/2024 | CHF 10.94 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 14/02/2024 | 2.04% |
Investment Objective: Pictet-Biotech HP CHF |
This Compartment applies a capital growth strategy by investing at least two-thirds of its total assets/total wealth in equities or similar securities issued by biopharmaceutical companies throughout the world (including emerging countries). However, in light of the particularly innovative nature of the pharmaceutical industry in North America and Western Europe, the vast majority of investments will be made in these regions. To capitalise on particularly innovative projects in the pharmaceuticals field, the Biotech Compartment may invest up to 10% of its net assets in Private Equity and/or unlisted securities. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Tazio Storni 26/05/2016 | ||
Marco Minonne 01/06/2020 | ||
Click here to see others | ||
Inception Date 23/10/2012 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI ACWI NR EUR | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Pictet-Biotech HP CHF | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Moderna Inc | Healthcare | 4.98 |
argenx SE ADR | Healthcare | 4.25 |
Viking Therapeutics Inc | Healthcare | 3.94 |
Biomarin Pharmaceutical Inc | Healthcare | 3.86 |
Blueprint Medicines Corp | Healthcare | 3.82 |
Increase Decrease New since last portfolio | ||
Pictet-Biotech HP CHF |